Topics:

Selected Cancer Drugs and Indications

Selected Cancer Drugs and Indications

Appendix 3: Selected Cancer Drugs and Indications

Newly approved or newly labeled by the US Food and Drug Administration (FDA), 2014

FDA Approvals

January 2014

Dabrafenib (Tafinlar)—for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Trametinib (Mekinist)—for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

February 2014

Ibrutinib (Imbruvica)—for the treatment of chronic lymphocytic leukemia.

April 2014

Ceritinib (Zykadia)—for the treatment of anaplastic lymphoma kinase–positive, metastatic non–small-cell lung cancer.

Mercaptopurine (Purixan)—for the treatment of acute lymphoblastic leukemia.

Ofatumumab (Arzerra)—for the treatment of chronic lymphocytic leukemia.

Ramucirumab (Cyramza)—for the treatment of metastatic, gastric or gastroesophageal junction adenocarcinoma.

Siltuximab (Sylvant)—for the treatment of multicentric Castleman disease.

July 2014

Belinostat (Beleodaq)—for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Idelalisib (Zydelig)—for the treatment of relapsed chronic lymphocytic leukemia.

August 2014

Bevacizumab (Avastin)—for the treatment of persistent, recurrent or metastatic cervical cancer.

September 2014

Pembrolizumab (Keytruda) for the treatment of unresectable or metastatic melanoma.

For additional information and an up-to-date listing of newly approved oncology drugs, visit the FDA’s website.

By clicking Accept, you agree to become a member of the UBM Medica Community.